文献速递重症综合管理与镇静镇痛呼吸衰竭与机械通气儿科与产科急症

吸入异氟烷用于重症监护机械通气患儿镇静(IsoCOMFORT):一项多中心、随机、活性对照、评估者设盲、非劣效性3期试验

Inhaled isoflurane for sedation of mechanically ventilated children in intensive care (IsoCOMFORT): a multicentre, randomised, active-control, assessor-masked, non-inferiority phase 3 trial.
PubMed 文献 · Lancet Respir Med · 2025-07-15
一句话结论在3–17岁危重机械通气患儿中,吸入异氟烷镇静在维持COMFORT-B目标镇静深度的时间百分比上非劣效于静脉咪达唑仑,可作为替代镇静药物。

IsoCOMFORT为在西班牙、法国、德国和英国19个儿科ICU开展的多中心、随机、活性对照、评估者设盲、非劣效性3期试验,纳入3–17岁需有创机械通气且预期镇静至少12小时的危重患儿,按2:1随机接受吸入异氟烷或静脉咪达唑仑镇静,计划镇静最长48小时(±6小时)。主要终点为无补救镇静情况下COMFORT-B评分处于个体预设目标范围的时间百分比,每2小时监测。全分析集92例中,异氟烷组最小二乘均值68.94%(95%CI 52.83–85.05),咪达唑仑组62.37%(44.70–80.04),差值6.57个百分点(95%CI −8.99至22.13),95%CI下限超过非劣效界值−9.36个百分点,达到非劣效。安全性集94例中,严重不良事件异氟烷组19/61(31%)、咪达唑仑组8/33(24%),均未被认为与研究治疗相关;两组各1例治疗相关严重低血压,异氟烷组3例因不良事件终止治疗,无治疗相关死亡。作者认为吸入异氟烷镇静效果非劣效于静脉咪达唑仑,为机械通气患儿提供了一种替代药物。

要点

  • 3–17岁危重机械通气患儿中,异氟烷组COMFORT-B目标范围时间百分比68.94%(95%CI 52.83–85.05)vs 咪达唑仑组62.37%(44.70–80.04),差值6.57个百分点(95%CI −8.99至22.13),达到非劣效(界值−9.36个百分点)。
  • 严重不良事件异氟烷组19/61(31%)vs 咪达唑仑组8/33(24%),均未被认为与研究治疗相关;两组各1例治疗相关严重低血压。
  • 异氟烷组3例因不良事件终止治疗;无治疗相关死亡。
  • 镇静计划最长48小时(±6小时),COMFORT-B每2小时评估一次,至少评估12小时。
  • 作者认为吸入异氟烷镇静非劣效于静脉咪达唑仑,为机械通气患儿提供替代药物。

适用人群与场景

  • 3–17岁危重患儿,需有创机械通气且预期镇静至少12小时,纳入西班牙、法国、德国和英国19个儿科ICU。

诊断标准与关键阈值

  • 基线时根据COMFORT Behaviour(COMFORT-B)量表预设个体化目标镇静深度范围,镇静剂量滴定至该范围。
  • 主要终点为非劣效性检验,界值−9.36个百分点。

处置流程与药物剂量

  • 随机按2:1分配至吸入异氟烷镇静或静脉咪达唑仑镇静,按年龄组、ICU入住原因(计划或非计划机械通气)和国家分层,区组大小3和6。
  • 镇静剂量滴定至基线预设的COMFORT-B目标范围,计划治疗最长48小时(±6小时)。
  • COMFORT-B每2小时监测一次,预期至少12小时(最长48±6小时)。

研究设计与关键结果

  • 多中心、随机、活性对照、评估者设盲、非劣效性3期试验,19个儿科ICU,96例随机(异氟烷组63例、咪达唑仑组33例),全分析集92例(平均年龄7.7岁[SD 4.1];女性35例[38%]、男性57例[62%])。
  • 主要终点:无补救镇静下COMFORT-B目标范围时间百分比,异氟烷组最小二乘均值68.94%(95%CI 52.83–85.05)vs 咪达唑仑组62.37%(44.70–80.04),差值6.57个百分点(95%CI −8.99至22.13),95%CI下限超过非劣效界值−9.36个百分点,达到非劣效。
  • 安全性集94例:严重不良事件异氟烷组19/61(31%)vs 咪达唑仑组8/33(24%),均未被认为与研究治疗相关;治疗相关严重低血压两组各1例;异氟烷组3例因不良事件终止治疗;无治疗相关死亡。

证据类型、等级与局限

  • 证据类型:多中心、随机、活性对照、评估者设盲、非劣效性3期试验。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 作者认为在危重儿童中,吸入异氟烷镇静效果非劣效于静脉咪达唑仑,为接受机械通气的儿童提供了一种替代药物。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Inhaled sedation for mechanical ventilation in patients who are critically ill is emerging as an alternative sedative strategy; however, data are scarce on its efficacy and safety in children, compared with intravenous sedation. The IsoCOMFORT trial aimed to compare the efficacy of inhaled sedation with isoflurane versus intravenous midazolam in the paediatric setting.

METHODS: IsoCOMFORT was a randomised, active-control, assessor-masked, non-inferiority phase 3 trial conducted across 19 paediatric intensive care units in Spain, France, Germany, and the UK. Children aged 3-17 years who were critically ill and required invasive mechanical ventilation and sedation for an expected duration of at least 12 h were randomly assigned (2:1) via an interactive web-response system to inhaled sedation with isoflurane or to intravenous sedation with midazolam. Randomisation was done in permuted blocks (sizes 3 and 6), stratified by age group, reason for intensive care unit admission (planned or unplanned mechanical ventilation), and country, with treatment allocation masked to outcome assessors. At baseline, a target range for sedation depth was prescribed based on the COMFORT Behaviour (COMFORT-B) scale, and sedation dosing was titrated to reach the target range. Sedative treatment was planned for up to 48 h (±6 h). The primary endpoint was the percentage of time that an adequate sedation depth was maintained, in the absence of rescue sedation, within the individually prescribed target range, as monitored every 2 h for an expected minimum of 12 h (up to 48±6 h) with the COMFORT-B scale. The primary endpoint was assessed for non-inferiority (margin -9·36 percentage points) in the full analysis set (all randomly assigned participants who received ≥6 h of the allocated study sedative and ≥3 masked COMFORT-B assessments), according to intention to treat. Safety was assessed in all participants who received study treatment. The trial was registered with ClinicalTrials.gov, NCT04684238, and EudraCT, 2020-000578-31, and is completed.

FINDINGS: Between Jan 14, 2021, and Jan 19, 2023, 96 children were randomly assigned: 63 to the isoflurane group and 33 to the midazolam group. 92 participants were included in the full analysis set (mean age 7·7 years [SD 4·1]; 35 [38%] female and 57 [62%] male). The least-squares mean percentage of time in the COMFORT-B target range was 68·94% (95% CI 52·83-85·05) in the isoflurane group and 62·37% (44·70-80·04) in the midazolam group. The least-squares mean difference between treatments was 6·57 percentage points (95% CI -8·99 to 22·13), indicating non-inferiority, with the lower bound of the 95% CI exceeding the non-inferiority margin of -9·36 percentage points). In the safety set (n=94), serious adverse events occurred in 19 (31%) of 61 participants in the isoflurane group and eight (24%) of 33 participants in the midazolam group, none of which were considered related to study treatment. Treatment-related severe hypotension occurred in one participant per group, and three participants in the isoflurane group discontinued treatment due to adverse events. No treatment-related deaths were reported.

INTERPRETATION: Among critically ill children, the effectiveness of sedation with inhaled isoflurane was non-inferior to that of intravenous midazolam, offering an alternative medication in children receiving mechanical ventilation.

FUNDING: Sedana Medical, Stockholm, Sweden.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Miatello J, Palacios-Cuesta A, Radell P, et al. Inhaled isoflurane for sedation of mechanically ventilated children in intensive care (IsoCOMFORT): a multicentre, randomised, active-control, assessor-masked, non-inferiority phase 3 trial. Lancet Respir Med. 2025. PMID: 40680761. doi:10.1016/S2213-2600(25)00203-6

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。